Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase

Journal of Viral Hepatitis

Volumn 14, Issue 9, 2007, Pages 661-666

  Fukai, K ^a   Zhang, K Y ^a   Imazeki, F ^a   Kurihara, T ^a   Mikata, R ^a   Yokosuka, O ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis; Hepatitis B virus; Lamivudine; Polymerase; Reverse transcriptase domain

Indexed keywords

DNA DIRECTED DNA POLYMERASE ALPHA; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; ENHANCER REGION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MICROBIAL SENSITIVITY TEST; MULTIVARIATE ANALYSIS; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SEROLOGY; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

EID: 34547888320     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00852.x     Document Type: Article

References (20)

1. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998 339 (2 61 68.
2. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 341 (17 1256 1263.
3. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998 27 (6 1670 1677.
4. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000 32 (1 129 134.
5. Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002 123 (6 1831 1838.
6. Tang S, Ho SK, Moniri K, Lai KN, Chan TM. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. Transplantation 2002 73 (1 148 151.
7. van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004 40 (6 1421 1425.
8. Buti M, Sanchez F, Cotrina M et al. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. J Infect Dis 2001 183 (8 1277 1280.
9. Puchhammer-Stockl E, Mandl CW, Kletzmayr J et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000 181 (6 2063 2066.
10. Ide T, Kumashiro R, Koga Y et al. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine. Am J Gastroenterol 2003 98 (9 2048 2051.
11. Usuda S, Okamoto H, Iwanari H et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999 80 (1 97 112.
12. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995 69 (9 5437 5444.
13. Fujiyama A, Miyanohara A, Nozaki C, Yoneyama T, Ohtomo N, Matsubara K. Cloning and structural analyses of hepatitis B virus DNAs, subtype adr. Nucleic Acids Res 1983 11 (13 4601 4610.
14. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 125 (6 1714 1722.
15. Akuta N, Suzuki F, Kobayashi M et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003 38 (3 315 321.
16. Huang YH, Wu JC, Chang TT et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003 10 (4 277 284.
17. Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 2004 39 (1 64 73.
18. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001 34 (4 Pt 1 785 791.
19. Wolters LM, Hansen BE, Niesters HG et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002 37 (2 253 258.
20. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004 78 (16 8524 8535.